

Global Non-Injectable Insulin Market Size study, by Product Type (Insulin Patches, Insulin Inhalers, Insulin Pens, Insulin Gels), by Therapeutic Area (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by End User (Hospitals, Home Care Settings, Diabetes Clinics), and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G6FF8B3AA420EN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,750.00 (Single User License)

ID: G6FF8B3AA420EN

Abstracts

Global Non-Injectable Insulin Market is valued approximately at USD 8.04 billion in 2023 and is anticipated to grow with a steady growth rate of more than 5.67% over the forecast period 2024–2032. As diabetes continues to evolve into one of the most pressing global health challenges, the need for more patient-centric and innovative insulin delivery systems has intensified. Non-injectable insulin solutions are reshaping the diabetes care paradigm by offering needle-free, user-friendly alternatives to traditional injections. These advancements include insulin inhalers, gels, and transdermal patches that not only eliminate the discomfort associated with syringes but also promote adherence through convenient administration. By enhancing the quality of life for both Type 1 and Type 2 diabetic populations, this market is catalyzing a shift from invasive management strategies to more lifestyle-integrated solutions.

The rise in global diabetes prevalence—driven by sedentary habits, obesity, and genetic predispositions—has placed unprecedented pressure on healthcare systems to adopt more efficient treatment protocols. Moreover, patient aversion to injections has long hindered timely initiation and sustained use of insulin therapy, making non-injectable alternatives a compelling proposition. Notably, regulatory agencies and R&D bodies

have begun accelerating approval cycles and funding pipelines for these therapies. With companies investing aggressively in the development of pulmonary and dermal insulin technologies, the market is seeing breakthroughs in absorption efficiency and dosing precision. However, high production costs, challenges in bioavailability, and limited long-term clinical data present obstacles that stakeholders must strategically navigate.

Innovation remains at the core of competition in the non-injectable insulin ecosystem. Key players are investing in platform technologies that integrate smart wearable devices with insulin patches to enable real-time glucose monitoring and automated dosing. At the same time, collaborations between biopharmaceutical firms and digital health startups are ushering in hybrid solutions that marry therapeutic delivery with AI-powered disease management. Additionally, efforts to improve the shelf life and thermal stability of non-injectable formulations are expanding their applicability in rural and low-resource settings, especially where refrigeration is a barrier. As intellectual property portfolios mature and patents expire, new entrants are expected to challenge incumbents through disruptive pricing models and localized manufacturing.

With personalized healthcare gaining traction, patient-centric designs—like dose-flexible insulin pens and discrete inhalers—are also transforming the user experience. The industry is increasingly aligning its offerings to specific therapeutic segments such as gestational diabetes, a growing concern among pregnant women globally. Market expansion is further supported by health campaigns encouraging early diagnosis and proactive disease management, especially in middle-income economies. Meanwhile, policy-level incentives for diabetes control, coupled with digital prescription infrastructures, are helping expand the footprint of non-injectable insulin, both online and in retail pharmacy networks.

Regionally, North America holds the lion's share of the market, fueled by strong reimbursement structures, tech-savvy healthcare infrastructure, and a growing population of insulin-dependent diabetics. Europe closely follows, supported by favorable healthcare regulations and robust patient advocacy for advanced insulin delivery methods. The Asia Pacific region is witnessing the fastest growth, driven by rising diabetes incidence, expanding healthcare access, and increasing awareness about novel treatment options in countries like India and China. Latin America and the Middle East & Africa are also catching up, thanks to global health alliances and local production initiatives targeting affordability and accessibility.

Major market player included in this report are:

Medtronic plc

Novo Nordisk A/S

Biocon Limited

Eli Lilly and Company

Sanofi S.A.

MannKind Corporation

Wockhardt Ltd.

Dance Biopharm Inc.

Intradose Pharma

TTP plc

Nemauro Medical Inc.

Vectura Group plc

Julphar

Tandem Diabetes Care, Inc.

Valeritas, Inc.

The detailed segments and sub-segment of the market are explained below:

By Product Type

Insulin Patches

Insulin Inhalers

Insulin Pens

Insulin Gels

By Therapeutic Area

Type 1 Diabetes

Type 2 Diabetes

Gestational Diabetes

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By End User

Hospitals

Home Care Settings

Diabetes Clinics

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Contents

CHAPTER 1. GLOBAL NON-INJECTABLE INSULIN MARKET EXECUTIVE SUMMARY

- 1.1. Global Non-Injectable Insulin Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Product Type
 - 1.3.2. By Therapeutic Area
 - 1.3.3. By Distribution Channel
 - 1.3.4. By End User
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL NON-INJECTABLE INSULIN MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Consumer's Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory Frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Environmental Considerations
 - 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL NON-INJECTABLE INSULIN MARKET DYNAMICS

3.1. Market Drivers

- 3.1.1. Rising global diabetes prevalence and needle aversion
- 3.1.2. Technological breakthroughs in pulmonary and transdermal delivery
- 3.1.3. Regulatory acceleration and increased R&D funding

3.2. Market Challenges

- 3.2.1. High production costs and bioavailability constraints
- 3.2.2. Limited long-term clinical data and market penetration hurdles

3.3. Market Opportunities

- 3.3.1. Integration of smart wearables with insulin patches
- 3.3.2. Collaborations between biopharma and digital health startups
- 3.3.3. Expansion into rural and low-resource settings

CHAPTER 4. GLOBAL NON-INJECTABLE INSULIN MARKET INDUSTRY ANALYSIS

4.1. Porter's Five Forces Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's Model
- 4.1.7. Porter's Impact Analysis

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunities

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspectives

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL NON-INJECTABLE INSULIN MARKET SIZE & FORECASTS

BY PRODUCT TYPE (2022–2032)

- 5.1. Segment Dashboard
- 5.2. Insulin Patches Revenue Trend, 2022 & 2032 (USD Million)
- 5.3. Insulin Inhalers Revenue Trend, 2022 & 2032 (USD Million)
- 5.4. Insulin Pens Revenue Trend, 2022 & 2032 (USD Million)
- 5.5. Insulin Gels Revenue Trend, 2022 & 2032 (USD Million)

CHAPTER 6. GLOBAL NON-INJECTABLE INSULIN MARKET SIZE & FORECASTS BY THERAPEUTIC AREA (2022–2032)

- 6.1. Segment Dashboard
- 6.2. Type 1 Diabetes Revenue Trend, 2022 & 2032 (USD Million)
- 6.3. Type 2 Diabetes Revenue Trend, 2022 & 2032 (USD Million)
- 6.4. Gestational Diabetes Revenue Trend, 2022 & 2032 (USD Million)

CHAPTER 7. GLOBAL NON-INJECTABLE INSULIN MARKET SIZE & FORECASTS BY REGION (2022–2032)

- 7.1. North America Market
 - 7.1.1. U.S. Market
 - 7.1.1.1. By Product Type (2022–2032)
 - 7.1.1.2. By Therapeutic Area (2022–2032)
 - 7.1.1.3. By Distribution Channel (2022–2032)
 - 7.1.1.4. By End User (2022–2032)
 - 7.1.2. Canada Market
- 7.2. Europe Market
 - 7.2.1. UK Market
 - 7.2.2. Germany Market
 - 7.2.3. France Market
 - 7.2.4. Spain Market
 - 7.2.5. Italy Market
 - 7.2.6. Rest of Europe Market
- 7.3. Asia Pacific Market
 - 7.3.1. China Market
 - 7.3.2. India Market
 - 7.3.3. Japan Market
 - 7.3.4. Australia Market
 - 7.3.5. South Korea Market

- 7.3.6. Rest of Asia Pacific Market
- 7.4. Latin America Market
 - 7.4.1. Brazil Market
 - 7.4.2. Mexico Market
 - 7.4.3. Rest of Latin America Market
- 7.5. Middle East & Africa Market
 - 7.5.1. Saudi Arabia Market
 - 7.5.2. South Africa Market
 - 7.5.3. Rest of Middle East & Africa Market

CHAPTER 8. COMPETITIVE INTELLIGENCE

- 8.1. Key Company SWOT Analysis
 - 8.1.1. Medtronic plc
 - 8.1.2. Novo Nordisk A/S
 - 8.1.3. Eli Lilly and Company
- 8.2. Top Market Strategies
- 8.3. Company Profiles
 - 8.3.1. Medtronic plc
 - 8.3.1.1. Key Information
 - 8.3.1.2. Overview
 - 8.3.1.3. Financial (Subject to Data Availability)
 - 8.3.1.4. Product Summary
 - 8.3.1.5. Market Strategies
 - 8.3.2. Novo Nordisk A/S
 - 8.3.3. Eli Lilly and Company
 - 8.3.4. Biocon Limited
 - 8.3.5. Sanofi S.A.
 - 8.3.6. MannKind Corporation
 - 8.3.7. Wockhardt Ltd.
 - 8.3.8. Dance Biopharm Inc.
 - 8.3.9. Intradose Pharma
 - 8.3.10. TTP plc
 - 8.3.11. Nemauro Medical Inc.
 - 8.3.12. Vectura Group plc
 - 8.3.13. Julphar
 - 8.3.14. Tandem Diabetes Care, Inc.
 - 8.3.15. Valeritas, Inc.

CHAPTER 9. RESEARCH PROCESS

9.1. Research Process

9.1.1. Data Mining

9.1.2. Analysis

9.1.3. Market Estimation

9.1.4. Validation

9.1.5. Publishing

9.2. Research Attributes

I would like to order

Product name: Global Non-Injectable Insulin Market Size study, by Product Type (Insulin Patches, Insulin Inhalers, Insulin Pens, Insulin Gels), by Therapeutic Area (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by End User (Hospitals, Home Care Settings, Diabetes Clinics), and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G6FF8B3AA420EN.html>

Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6FF8B3AA420EN.html>